Non‑factor therapies continue to reshape the treatment landscape for hemophilia by offering novel approaches to rebalancing coagulation. Hympavzi (marstacimab), a subcutaneously administered anti‑TFPI therapy, represents an important new option informed by both robust clinical data and emerging real‑world experience.
This symposium will explore the scientific rationale, mechanism of action, clinical trial evidence, and practical considerations surrounding the use of Hympavzi (marstacimab) in hemophilia management. Faculty will review the foundational science behind Hympavzi (marstacimab) and summarize key findings from the Phase 3 clinical development program.
In addition, the session will feature a discussion with hematologists who have real‑world experience integrating Hympavzi (marstacimab) into clinical practice. Their perspectives on patient selection, breakthrough bleeds, surgical data, monitoring, and initial outcomes will provide attendees with practical insights into how Hympavzi (marstacimab) may be incorporated into the evolving therapeutic landscape of hemophilia care.